



FOR IMMEDIATE RELEASE

Theraclone Sciences Named a 2011 Fierce 15 Biotech by FierceBiotech

Seattle, WA – September 6, 2011 – Theraclone Sciences, a therapeutic antibody discovery and development company, today has been named by FierceBiotech as one of 2011's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. Theraclone Sciences is using its I-STAR™ technology for the rapid screening, identification and development of broadly protective therapeutic human monoclonal antibodies for a variety of indications.

"This has been a big year for Theraclone," said John Carroll, editor-in-chief of FierceBiotech. "The biotech – which is in the business of finding and developing the most potent antibodies known in nature - has struck a Big Pharma collaboration pact with Pfizer, recently unveiled a slate of antibodies that could work against a number of HIV strains and set itself up for a quick top-up financing on the venture side. Now Theraclone is preparing to enter the clinic with its lead program and negotiate one or two more antibody discovery deals with new partners in the near term."

"The Fierce 15 designation is recognition of Theraclone's successful and proven approach to discover new, potent antibodies to address medical needs of global importance, such as influenza, human cytomegalovirus and HIV," said Steven Gillis, Ph.D., Executive Chairman and acting CEO of Theraclone. "We are honored to join this list of innovative, creative companies."

An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day's top stories. Every year, FierceBiotech evaluates hundreds of private companies for its annual list based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's ninth annual Fierce 15 selection. A complete list of Fierce 15 companies — the online newsletter's ninth annual selection — is available online at www.fiercebiotech.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at www.fiercebiotech.com.

About Theraclone Sciences

Theraclone Sciences is a Seattle-based biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The company's technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human subjects. Human monoclonal antibodies can be rapidly isolated using the I-STAR™ discovery platform and scaled for industrial production. Such human



antibody drug candidates may be uniquely safe and relevant to combating disease across broad patient populations. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, MPM Capital, Amgen Ventures and Alexandria Real Estate Investment. For additional information, please visit www.theraclone-sciences.com.

###

Media Contact:

Jacqui Miller or Doug MacDougall
MacDougall Biomedical Communications
781-235-3060